AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...
On 31 March, at the American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago, US, the findings from the PURSUIT Phase IIb clinical trial were presented. The study evaluated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback